Approximately one-third of all human breast tumours is hormone-responsive, i.e. the growth of the tumour cells is stimulated by oestradiol [ 11. The metastases of such tumours are commonly treated with anti-oestrogenic drugs, e.g. Tamoxifen 121. It is well established that anti-oestrogens compete with oestradiol for binding to the oestrogen receptor [3] and that their potency is related to their affinity for the receptor. However, only approximately 55% of breast tumours containing oestrogen receptors are growth-inhibited by anti-oestrogens. Furthermore, it has been shown that, for certain responses, anti-oestrogens may act as full or partial oestrogen agonists.
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The growth of the human breast cancer cell lines, MCF-7 and ZR-75-1, is oestrogen dependent in culture [4, 51 and may serve as a model of human hormone-responsive breast cancer in vitro. We possess two cDNAs, pS2 [6] and pLIV-1 (71 that were isolated on the basis of their induction by oestradiol in MCF-7 and ZR-75-1 cells, respectively. We have examined the responses of both genes to antioestrogens and to other steroid hormones in both MCF-7 and ZR-75-1 cells. Cells were grown for 6 days (three medium changes) in Phenol Red-free, RPMl 1640 medium with 10% (v/v) dextran-charcoal-stripped newborn calf serum, to deplete them of steroid hormones. The cells were then transferred to the same medium supplemented with either oestradiol ( l o -' M) or 5a-dihydrotestosterone (lo-' M ) or dexamethasone ( l w 7 M) or tamoxifen ( lo-") o r 4-hydroxytamoxifen ( l o -' M ) or to medium without addition. After culture for 3 further days, the cells were harvested and their total RNA isolated. The RNA was transferred to a nylon membrane (Hybond N, Amersham) by the 'dot blot' procedure and hybridized to "P-labelled pLIV-1 cDNA. After hybridization (45"C, 18 h), the membrane was washcd to high stringency (final wash, 0.1 x SSPE, 20°C 171) and then autoradiographed (Fig. I ). The same membrane was then stripped of probe and rehybridized to "P-labelled pS2 cDNA (Fig. 1 ) .
It can be seen that both pLIV-I and pS2 are expressed in an oestrogen-responsive fashion in both cell-lines ( Fig. 1 a  and b, tracks 1 -4, 6, 9) . Expression o f both genes is also induced in MCF-7 cells by 5 a-dihydrotestosterone ( Fig. 1 a  and 6 , track 5). Interestingly, pLIV-I is strongly induced by the glucocorticoid, dexamethasone, but pS2 is unresponsive to this hormone (Fig. l a and b, track 7) . The two genes also differ in their response to anti-oestrogens. pLIV-I is markedly induced by tamoxifen (Fig. la, track X) , whereas the level of pS2 expression in tamoxifen-treated ZR-75-1 cells (Fig. 1 b, track 8 ) is indistinguishable from that in control cells (Fig. 1 b, track 1 ). 4-Hydroxytamoxifen stimulates a slight increase in pLIV-1 (Fig. l a , track lo) , but is without detectable effect on pS2. Using a more sensitive hybridiza- 
